FULGENT GENETICS, INC. Business Acquisition, Pro Forma Net Income (Loss)
FULGENT GENETICS, INC. (FLGT) reported Business Acquisition, Pro Forma Net Income (Loss) of -$24.51 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-01.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2026-05-01
- FULGENT GENETICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2026-03-31 was -$24.51M.
- FULGENT GENETICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2025-09-30 was -$6.50M.
- FULGENT GENETICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2025-03-31 was -$13.69M.
- FULGENT GENETICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2024-09-30 was -$14.44M.
- FULGENT GENETICS, INC. business acquisition, pro forma net income (loss) for fiscal 2022 was $140.29M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|
| 2026-03-31 | -$24.51M 10-Q · filed 2026-05-01 | ||
| 2025-09-30 | -$6.50M 10-Q · filed 2025-11-07 | -$31.60M 10-Q · filed 2025-11-07 | |
| 2025-03-31 | -$13.69M 10-Q · filed 2026-05-01 | ||
| 2024-09-30 | -$14.44M 10-Q · filed 2025-11-07 | -$30.80M 10-Q · filed 2025-11-07 | |
| 2022-12-31 | $140.29M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |